Clinical trials: Circulating Tumor Cells, open to volunteers
Lung Cancer
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
The investigators aim to identify novel circulating methylated biomarkers for early lung cancer detection as well as to develop new technologies that are clinically applicable with high sensitivity and specificity.
- Trial name
- NCT04814407
- Testing
- Blood-derived DNA methylation detection
- Where
- Taiwan
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Lung Cancer Stage III
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- MRD-LUNG (NCT06111807)
- Testing
- ctDNA
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 248 people
- Sponsor
- University Medical Center Groningen
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Lung Cancer, Circulating Tumor DNA
NSCLC Liquid Biopsies and Exhaled VOC
The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for…
- Trial name
- NCT06707519
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Melanoma, Circulating Tumor Cells
In Vivo Liquid Biopsy of Melanoma (Cytophone)
The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body.
- Conditions
- Melanoma, Circulating Tumor Cells, Metastatic Melanoma, Diagnosis
- Trial name
- Cytophone (NCT06488365)
- Testing
- Cytophone
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Cytoastra
Cancer, Lung Cancer, Non-Small Cell
Analysis of Circulating Tumor Markers in Blood - ALCINA 5
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency…
- Trial name
- ALCINA 5 (NCT07060950)
- Testing
- Blood sampling C1
- Where
- France
- Volunteers
- 620 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Cervical Cancer, Anal Cancer
Detecting HPV DNA in Anal and Cervical Cancers
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer.
- Conditions
- Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma
- Trial name
- NCT04857528
- Testing
- Radiation Treatment With or Without Chemotherapy, Blood Sample Collection, HPV Genotyping (HPV DNA Test)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Waldenstrom's Disease, Waldenstrom Macroglobulinemia
Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
Waldenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood.
- Trial name
- SLP-rares (NCT04893564)
- Testing
- bone marrow sample, blood sample
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have favorable outcomes and how well they do depends on the specific details about the patient and their cancer.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
- Trial name
- SAVAL (NCT06088381)
- Testing
- Experimental Observation, Observation per Standard of Care, Adjuvant Treatment per Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Maryland, Baltimore
Diagnosis of Soft Tissue Sarcoma (STS)
Improved Management of Soft Tissue Sarcomas Patients With an Optimized and Innovative Sorting Technology for Circulating Tumor Cells
This trial is a monocentric, clinico-biological cohort study with prospective enrollment, aiming to develop a method for detecting and sorting CTCs (circulating tumour cells) from liquid biopsies (fresh blood samples) in patients…
- Trial name
- LIGHT-CTC (NCT07401355)
- Testing
- Collection of tumor and blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Leon Berard
Tumor Cells, Circulating, Venous Thrombosis
The Correlation Between Circulatory Tumor Cells and Venous Thrombosis
Research indicates a strong correlation between cancer and thrombosis, with approximately 20% of blood clots in the U.S. being cancer-related, according to CDC data.
- Trial name
- NCT06672250
- Testing
- CTCs/CTMs culture
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Bladder Cancer, Urothelial Carcinoma
Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer
RETAIN-3 is a phase II study in patients with cT2-T3N0M0 muscle-invasive urothelial carcinoma of the bladder. Participants will receive neoadjuvant enfortumab vedotin and pembrolizumab followed by clinical and biomarker-based…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
- Trial name
- RETAIN-3 (NCT07908979)
- Testing
- Enfortumab vedotin, Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Fox Chase Cancer Center
Oncology
Potential of Moderate Whole Body Hyperthermia to Enhance Response
Using moderate whole-body hyperthermia (mWBH) in tumor patients to see the influence on circulating tumor cells, tumor response, quality of life, fatigue, psyche, immune response and tumor microenvironment
- Trial name
- POWER (NCT05821166)
- Testing
- moderate Whole Body Hyperthermia (mWBH)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Charite University, Berlin, Germany
Small Cell Lung Cancer Extensive Stage
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and…
- Trial name
- NCT05066945
- Testing
- Observation
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Glioma, Malignant
Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs
MicroRNAs are small non-coding RNAs involved in the post-transcriptional regulation of genes and, consequently, of intracellular signalling pathways that govern cellular behaviour (Komatsu et al., 2023).
- Trial name
- GliomiR (NCT06203496)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Caen
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
This phase II trial studies how well using circulating tumor deoxyribonucleic acid (DNA) to guide lower dose radiation therapy works in treating patients with human papillomavirus infection (HPV)-associated oropharyngeal cancer.
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06323460
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Non Small Cell Lung Cancer
Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer
This observational study will evaluate whether a blood test can detect the return of non-small cell lung cancer at least three months before it is identified on routine imaging.
- Trial name
- NCT07854769
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Non-small Cell Lung Cancer
Multiomics Tumor Evolution Model of NSCLC
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be…
- Trial name
- NCT05352035
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Melanoma
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular…
- Conditions
- Breast Cancer, Melanoma, Gastrointestinal Neuroendocrine Tumor
- Trial name
- NIP IT! (NCT05196087)
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- University Health Network, Toronto
Non-small Cell Lung Cancer
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
- Trial name
- NCT03791034
- Where
- South Korea
- Volunteers
- 700 people
- Sponsor
- Samsung Medical Center